Michael Hallek to Rituximab
This is a "connection" page, showing publications Michael Hallek has written about Rituximab.
Connection Strength
0.794
-
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14; 127(2):208-15.
Score: 0.336
-
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402.
Score: 0.107
-
HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation? Infection. 2019 Apr; 47(2):293-300.
Score: 0.105
-
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017 Sep; 92(9):946-965.
Score: 0.096
-
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol. 2015; 11(1):51-9.
Score: 0.080
-
COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia. 2020 08; 34(8):2225-2229.
Score: 0.029
-
Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. Biomed Res Int. 2018; 2018:1023490.
Score: 0.025
-
Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 09; 367(6):520-31.
Score: 0.017